Acuta Capital Partners’s United Therapeutics UTHR Stock Holding History

Acuta Capital Partners’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.21M	Hold	2,224	–	–	0.84%	21
2026 Q1	$1.32M	Sell	2,224 -72	-3%	-$35.9K	0.93%	21
2025 Q4	$1.12M	Hold	2,296	–	–	0.76%	20
2025 Q3	$963K	Buy	+2,296	New	+$772K	0.99%	22
2023 Q2	–	Sell	-23,500	Closed	-$5.26M	–	42
2023 Q1	$5.26M	Sell	23,500 -9,500	-29%	-$2.34M	3.88%	9
2022 Q4	$9.18M	Buy	33,000 +5,500	+20%	+$1.39M	5.65%	5
2022 Q3	$5.76M	Buy	27,500 +14,500	+112%	+$3.24M	2.48%	15
2022 Q2	$3.06M	Buy	+13,000	New	+$2.64M	1.71%	19
2021 Q4	–	Sell	-3,000	Closed	-$554K	–	52
2021 Q3	$554K	Buy	+3,000	New	+$591K	0.2%	45

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Acuta Capital Partners's UTHR Position: Q2 2026 in Review

Acuta Capital Partners held its United Therapeutics (UTHR) position steady in Q2 2026 at 2,224 shares worth $1.21M. The position accounts for 0.84% of the portfolio, ranked #21.

Acuta Capital Partners first reported a position in UTHR in Q3 2021 and has held it in 9 quarters since. The position peaked at $9.18M in Q4 2022. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Acuta Capital Partners held 2,224 shares of United Therapeutics worth $1.21M as of Q2 2026.
Acuta Capital Partners left its United Therapeutics share count unchanged in Q2 2026.
United Therapeutics made up 0.84% of Acuta Capital Partners's portfolio in Q2 2026, its #21 holding.
Acuta Capital Partners first reported a position in United Therapeutics in Q3 2021 and has held it in 9 quarters since.
Acuta Capital Partners's United Therapeutics position peaked at $9.18M in Q4 2022.
882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.